Reactivity: human, mouse, rat
Articlecode: 66-P746-81
Contents: Neu (C18) Blocking Peptide
Catalog Number: 66-P746
Sizes: 50 ug
Formulation: Each vial contains 100 ìg of peptide in 0.5 ml PBS with 0.1% NaN3 and 100 ìg BSA.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.
|
|
|
Available Formats of This Product
|
Cat. No.
|
Format
|
Excite
(nm)
|
Emit
(nm)
|
Reported Applications
|
66-P746
|
|
N/A
|
N/A
|
|
Description
This is a peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2). The Neu/HER-2 (also known as EGFR-2 or ErbB-2) is a transmembrane tyrosine kinase receptor and a well-defined tumor antigen. Neu/HER-2 is a shared antigen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast, ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-existent immune response to Neu/HER-2 (1,2). Neu/HER-2 amplification/overexpression confers more aggressive and malignant characteristics on breast cancer cells. Patients with Neu/HER-2-amplified breast cancer have a worse prognosis than those with normal Neu/HER-2 expression (3).
Usage
For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.
Related Products
Cat. 14-6746 Purified anti-mouse/human/rat Neu polyclonal (clone Polyclonal)
References
1. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Int J Endocr Relat Cancer 2002 Mar;9(1):33-44.
2. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001 Jul;2(2):129-35; discussion 136-7.
3. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001 Dec;28(6 Suppl 18):43-7
|
